Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer

Trial Profile

Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Malignant pleural effusion; Non-small cell lung cancer; Pericardial effusion
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 01 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 29 Mar 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top